Skip to main content
Fig. 9 | Lipids in Health and Disease

Fig. 9

From: Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases

Fig. 9

Proposed uptake/metabolism of LysoPC in tumour cells. The majority of LysoPC is extracellularly degraded to GlyceroPC and FFA by a LysoPC degrading factor. This factor – probably a LysoPLA – is partly released into the supernatant of the tumour cells. The resulting extracellular FFA can subsequently be taken up and incorporated into membrane PL and neutral lipids. Excess of neutral lipids can be stored as LD. Another possible uptake route for LysoPC is its incorporation into the cellular membrane as a whole molecule, where it becomes part of the Lands’ Cycle: the deacylation and reacylation process

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X